. 2007 Aug;93(8):1001–1007. doi: 10.1136/hrt.2006.088211

Table 5 Lp‐PLA2 and cardiovascular risk.

Study	Measure	Relative risk (95% CI)
Kardys et al²³	Measures of extracoronary atherosclerosis	1.86 (1.01 to 3.43) in men
Kardys et al²³	Measures of extracoronary atherosclerosis	1.60 (1.08 to 2.37) in women
Ballantyne et al²⁴	Ischaemic stroke	1.91 (1.15 to 3.18)†
Khuseyinova et al²⁵	Coronary artery disease	2.04 (1.19 to 3.48)*
Oei et al²⁶	CHD	1.97 (1.28 to 3.02)*
	Stroke	1.97 (1.03 to 3.79)*
Packard et al⁸	CHD, death, myocardial infarction, revascularisation	1.18 (1.05 to 1.33)‡
Blake et al⁹	CHD, death, myocardial infarction, stroke	1.17 (0.45 to 3.05)*
Koening et al²⁷	CHD, death, myocardial infarction	1.21 (1.01 to 1.45)‡
Ballantyne et al¹⁰	CHD, death, myocardial infarction, revascularisation	1.15 (0.81 to 1.63)†

CHD, coronary heart disease.

*Lowest quartile as reference; †lowest tertile as reference; ‡increase by 1SD of Lp‐PLA2 activity.